Impact of MAOA Gene Polymorphism on the Efficacy of Antidepressant Treatment and Craving Severity for Betel Quid Use Disorder
International Journal of Molecular Sciences · 2024
DOI: 10.3390/ijms25179221 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Chung-Chieh Hung und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan. Hauptthemen laut MEDLINE: Monoamine Oxidase, Polymorphism, Single Nucleotide, Areca, Antidepressive Agents. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Chung Shan Medical University Hospital, China Medical University Hospital, Taiwan Ministry of Health and Welfare Clinical Trial Center.
Abstract (Originalsprache)
Betel quid (BQ) use disorder (BUD) is prevalent in many Asian countries, impacting approximately 600 million people. We conducted a randomized clinical trial to analyze the impact of MAOA genetic variations on the severity of BQ craving. This was measured using DSM-5 criteria and the Yale–Brown Obsessive–Compulsive Scale modified for betel quid use (Y-BOCS-BQ). Participants were grouped according to the severity of BUD and MAOA gene single-nucleotide polymorphism (SNP) rs5953210 genotypes. The Y-BOCS-BQ scores were assessed at baseline (week 0) and during follow-up at weeks 2, 4, 6, and 8. The AA genotype group showed significantly greater reductions in Y-BOCS-BQ at weeks 2 (p = 0.0194), 4 (p = 0.0078), 6 (p = 0.0277), and 8 (p = 0.0376) compared to the GG genotype group. Additionally, within the antidepressant group, the AA genotype showed significant reductions in the Y-BOCS-BQ scores at weeks 2 (p = 0.0313), 4 (p = 0.0134), 6 (p = 0.0061), and 8 (p = 0.0241) compared to the GG genotype. The statistical analysis revealed a significant interaction between the treatment and placebo groups based on MAOA genotypes, with the AA genotype in the treatment group exhibiting a more pronounced decrease in Y-BOCS-BQ score (p interaction
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan.
- Department of Psychiatry, Chung Shan Medical University Hospital, Taichung 40201, Taiwan.
- Department of Medical Research, China Medical University Hospital, Taichung 40447, Taiwan.
- Graduate Institute of Toxicology, College of Medicine, National Taiwan University, Taipei 10051, Taiwan.
- School of Dentistry, College of Dental Medicine, Kaohsiung Medical University, Kaohsiung 80708, Taiwan.
- Institute of Biomedical Sciences, National Sun Yat-Sen University, Kaohsiung 80424, Taiwan.
ORCID-Profile: Chung-Chieh Hung, Ying-Chin Ko, Ping-Ho Chen, Chia-Min Chung
Förderung
- Chung Shan Medical University Hospital
- China Medical University Hospital
- Taiwan Ministry of Health and Welfare Clinical Trial Center
- Chung Shang Medical University Hospital
Zitieren
APA
Hung, C. C., Ko, Y. C., Chen, P. H., & Chung, C. M. (2024). Impact of MAOA Gene Polymorphism on the Efficacy of Antidepressant Treatment and Craving Severity for Betel Quid Use Disorder. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25179221
Vancouver
Hung CC, Ko YC, Chen PH, Chung CM. Impact of MAOA Gene Polymorphism on the Efficacy of Antidepressant Treatment and Craving Severity for Betel Quid Use Disorder. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25179221
BibTeX
@article{Hung2024,
author = {Hung, Chung-Chieh and Ko, Ying-Chin and Chen, Ping-Ho and Chung, Chia-Min},
title = {Impact of MAOA Gene Polymorphism on the Efficacy of Antidepressant Treatment and Craving Severity for Betel Quid Use Disorder},
journal = {International Journal of Molecular Sciences},
year = {2024},
doi = {10.3390/ijms25179221}
}
EUVIMED